- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02759796
Fluorescence Angiography in the Assessment of DIEP Flap Perfusion
April 21, 2017 updated by: Instituto de Investigación Hospital Universitario La Paz
Indocyanine Green Fluorescence Angiography in the Assessment of Deep Inferior Epigastric Perforator (DIEP) Flap Perfusion
It is a single-center, prospective, randomized and controlled study focused in microsurgical autologous breast reconstruction.
It involves applying indocyanine green (ICG) angiography for the study of the vascularization of DIEP flaps.
The aim of the study is to determine whether there are differences in complications and aesthetic results when ICG is used to discard the poorly vascularized areas of the flap.
The study includes adult women undergoing unilateral DIEP flap breast reconstruction.
The calculated sample size is 60 patients.
There are two groups.
In group 1, the investigators use the usual clinical criteria to discard the poorly vascularized areas of the flap.
In group 2, the investigators use the ICG to shape the flap.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Madrid, Spain, 28046
- La Paz University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Mastectomized adult female patient
- Abdominal flap unilateral breast reconstruction indication
- Alloplastic breast reconstruction sequelae
- Enough amount of abdominal dermofat tissue to shape a breast with a primary closure of the donor site
Exclusion Criteria:
- DIEP flap bilateral breast reconstruction indication
- Previous abdominoplasty surgery
- Untreated psychiatric disease
- Untreated infection
- Indocyanine green or iodine hypersensitivity
- Hyperthyroidism, thyroid adenoma or thyroid autonomy
- Any concomitant disease or condition that, in the opinion of the investigator, can make the patient unsuitable to receive a microsurgical technique or to join the research.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Clinical assessment of flap perfusion
Tailoring the flap according to clinical assessment of flap perfusion
|
After microvascular anastomosis is performed, the investigators clinically assess flap vascularization and the well vascularized tissue is marked by means of a dermographic pencil.
Then the investigators administer 0,2mg/kg of ICG intravenously.
The vascularization of the flap is also checked by means of the Photo Dynamic Eye (Pulsion Medical System) but finally the decision of discarding the poorly vascularized areas of the flap is made by clinical assessment.
|
EXPERIMENTAL: Angiography assessment of flap perfusion
Tailoring the flap according to ICG Angiography assessment of flap perfusion
|
After microvascular anastomosis is performed, the investigators administer 0,2mg/kg of ICG intravenously.
Then the investigators check the vascularization of the flap by means of the Photo Dynamic Eye (Pulsion Medical System) and the poorly vascularized areas of the flap are discarded guided by ICG perfusion test.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with fat necrosis as assessed by physical examination
Time Frame: Six months postoperatively
|
Six months postoperatively
|
Number of participants with fat necrosis as assessed by ultrasonography
Time Frame: Six months postoperatively
|
Six months postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with flap failure as assessed by physical examination
Time Frame: From intraoperative moment to one week postoperatively
|
From intraoperative moment to one week postoperatively
|
Number of participants with wound infection as assessed by physical examination
Time Frame: From one day postoperatively to two weeks postoperatively
|
From one day postoperatively to two weeks postoperatively
|
Number of participants with wound healing delay as assessed by physical examination
Time Frame: From two weeks postoperatively to two months postoperatively
|
From two weeks postoperatively to two months postoperatively
|
Number of participants with reoperation
Time Frame: From immediate postoperative moment to one year postoperatively
|
From immediate postoperative moment to one year postoperatively
|
Flap perfusion index as assessed by IC-CALC software (Pulsion Medical System)
Time Frame: Intraoperatively
|
Intraoperatively
|
Flap weight (grams)
Time Frame: Intraoperatively
|
Intraoperatively
|
Flap length (centimeters)
Time Frame: Intraoperatively
|
Intraoperatively
|
Breast-Q questionnaire (preoperative reconstruction module) to measure patient preoperative status
Time Frame: A preoperative test in the last week before surgery
|
A preoperative test in the last week before surgery
|
Breast-Q questionnaire (postoperative reconstruction module) to measure patient postoperative status
Time Frame: A postoperative test one year after surgery
|
A postoperative test one year after surgery
|
ICG security (Number of participants with tachycardia, exanthema and anaphylactic shock as assessed by physical examination and intraoperative monitoring)
Time Frame: Intraoperatively
|
Intraoperatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Luis Landín Jarillo, MD, PhD, La Paz University Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (ACTUAL)
April 1, 2017
Study Completion (ACTUAL)
April 1, 2017
Study Registration Dates
First Submitted
April 5, 2016
First Submitted That Met QC Criteria
April 29, 2016
First Posted (ESTIMATE)
May 3, 2016
Study Record Updates
Last Update Posted (ACTUAL)
April 24, 2017
Last Update Submitted That Met QC Criteria
April 21, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- idipaz
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Tailoring the flap according to clinical assessment
-
Institute of Biophysics and Cell Engineering of...Belarusian State Medical UniversityCompleted
-
Tufts UniversityNot yet recruiting
-
Assistance Publique Hopitaux De MarseilleUnknownInfective Endocarditis (IE)France
-
Institute of Biophysics and Cell Engineering of...Belarusian State Medical UniversityNot yet recruiting
-
Institute of Biophysics and Cell Engineering of...Belarusian State Medical UniversityNot yet recruitingBladder Cancer | Renal CancerBelarus
-
Institute of Biophysics and Cell Engineering of...The Republican Center for Research and Practice in OtolaryngologyNot yet recruitingAllergic Rhinitis | Rhinosinusitis Chronic
-
Institute of Biophysics and Cell Engineering of...Belarusian State Medical UniversityCompletedSystemic Lupus ErythematosusBelarus
-
Medical University of ViennaCompleted
-
Sun Yat-sen UniversityRecruitingPituitary Adenoma | Neuroendocrine TumorsChina
-
Institute of Biophysics and Cell Engineering of...Belarusian State Medical UniversityEnrolling by invitationAge-Related Macular DegenerationBelarus